2018年全球组织诊断市场将达40亿美元

千姿百态

日前，美国知名市场调研机构MarketsandMarkets发布的最新研究报告显示，全球组织诊断市场预计将以近6.97%的年度复合增长率（CAGR）增长，并在2018年达到39.24亿美元。

组织诊断是一套重要的技术，主要用于癌症的诊断、监控和管理。该市场产品包括仪器、试剂和试剂盒，用于确定疾病的阶段、预后和治疗过程，包括监测癌症对药物的治疗反应。不断增长的全球癌症发病率、组织诊断产品的应用（如伴随诊断用于癌症的个性化治疗）、全球人口老龄化，是驱动全球组织诊断市场增长的3个最重要的因素。

根据世界卫生组织（WHO）下属国际癌症研究机构（IARC）发布的全球癌症状况的最新数据——2012年全球肿瘤流行病统计数据（GLOBOCAN2012），在2012年，全球新增1410万癌症病例及820万癌症相关死亡记录。根据GLOBOCAN的统计数据，WHO和IARC预测，到2025年，全球范围内将每年新增约1930万例癌症。

该报告将全球组织诊断市场按技术、疾病、产品、最终用户和地理进行了划分。按技术划分，组织诊断分为免疫组化（IHC）、原位杂交（ISH）、数字化病理（Digital pathology & Workflow）、特殊染色，其中，免疫组化（IHC）占有最大的市场份额，鉴于IHC产品（如伴侣诊断）在癌症个性化治疗方面的日益应用，该细分市场预计将在2013-2018预测期内具有最高的CAGR。

按疾病划分，组织诊断市场可细分为乳腺癌、胃癌、淋巴癌、前列腺癌、非小细胞肺癌及其他疾病。其中，由于不断快速增长的发病率，乳腺癌细分市场占有最大的市场份额，并在预测期内具有最高的CAGR。乳腺癌是女性中最常见的一类癌症，其确诊高度依赖于组织诊断。

按最终用户划分，组织诊断市场可细分为医院、实验室及其他。由于组织诊断主要应用于癌症诊断。因此，医院细分市场仍将占有最大的市场份额，而研究实验室细分市场在预测期内将具有最高的CAGR，但仍将保持较低的水平。

按地理划分，美国占有组织诊断全球市场的最大份额。美国于2010年3月推出的《患者保护和负担得起的医疗法》（PPACA）预计将扩大超过3300万美国公民对保险的获取，将带动这一重要地理区域对晚期癌症诊断的需求，包括组织诊断。另一方面，金砖四国（BRIC，指巴西、俄罗斯、印度及中国）和全球其他地理区域（RoW）均预计将在预测期内具有较高的CAGR，这些市场的主要推动力为庞大且激增的老龄化人口及广阔的未开发潜力。

根据报告内容，组织诊断市场的主要参与者包括：罗氏诊断（Roche Diagnostics）、雅培（Abbott）、赛默飞（Thermo Fisher Scientific）、安捷伦（Agilent）、Danaher公司。其他重要参与者包括Biogenex实验室、Sigma-Aldrich公司、Cell Signaling Technology公司、BioSB公司和生命技术（Lif Technologies）。（生物谷Bioon.com）

英文原文：Advanced Cancer Diagnostics Market Worth $3，924.01 Million by 2018 - New Report by MarketsandMarkets

The “Tissue Diagnostics Market by Technology (Immunohistochemistry， in Situ Hybridization， Digital pathology & Workflow， Special Staining)， Disease (Breast Cancer， Gastric Cancer， Lymphoma， Prostate Cancer， Non Small Cell Lung Cancer and Others)， Product (Instruments and Consumables)， End-Users (Hospitals， Pharmaceutical companies， Research Laboratories， Contract Research Organizations and Others) & by Region (The Americas， Europe， BRIC， Japan & RoW) - Trends & Forecast to 2018” provides a detailed overview of the major drivers， restraints， challenges， opportunities， current market trends， and strategies impacting the global tissue diagnostics market along with the estimates and forecasts of the revenue and share analysis.

The global tissue diagnostics market is expected to grow at a CAGR of close to 6.97% between 2013 and 2018， to reach $3，924.01 million by 2018.

Tissue diagnostics are an important set of techniques， primarily used for the diagnosis， monitoring and management of cancer. The market includes instruments， reagents and kits used to determine the stage， prognosis， and treatment course of the disease. Increasing global incidences of cancer， the adoption of tissue diagnostic products as companion diagnostics in personalized medicine for cancer and the rapidly aging global population are expected to be the three most important growth drivers for the global market.

The report segments this market by technology， disease， product， end user and geography. The IHC technology segment commanded the largest share of the global market and is also poised to grow at the highest CAGR between 2013 and 2018， due to the increasing use of IHC products as companion diagnostics in personalized medicine for cancer.

Due to its rapidly increasing incidence， the breast cancer disease segment commanded the largest share of the global market. Breast cancer is the most common form of cancer in women and is highly amenable for tissue diagnostics. It is also poised to grow at the highest CAGR between 2013 and 2018.

Tissue diagnostics finds primary application for diagnosis of cancer. As such， the hospital end-user segment commanded the largest share of the global market， while the research laboratories end-user segment is poised to grow at the highest CAGR between 2013 and 2018. The use of tissue diagnostic products for research purposes is expected to remain low.

The Americas accounted for the largest share of the global market. The Patient Protection and Affordable Care Act (PPACA) introduced in the U.S. in March 2010 is expected to expand insurance access to more than 30 million U.S. citizens. This is expected to drive the demand for advanced cancer diagnostics， including tissue diagnostics， in this important geographic segment. On the other hand， the BRIC and RoW geographic segments are expected to grow rapidly at a higher CAGR in the forecast period between 2013 and 2018， owing to the large and rapidly aging population， and large untapped potential of these markets.

The major players in the tissue diagnostics market are Roche Diagnostics (Switzerland)， Abbott Laboratories (U.S.)， Thermo Fisher Scientific (U.S.)， Agilent Technologies (U.S.)， Danaher Corporation (U.S.). Other important players in this market are Biogenex Laboratories (U.S.)， Sigma-Aldrich (U.S.)， Cell Signaling Technology (U.S.)， Bio SB (U.S.) and Life Technologies (U.S.).

来源：生物谷